BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16979440)

  • 1. Cure of incurable lymphoma.
    DeNardo GL; Sysko VV; DeNardo SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
    DeNardo GL; DeNardo SJ; Balhorn R
    Cancer Biother Radiopharm; 2008 Aug; 23(4):383-97. PubMed ID: 18771343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
    Juweid ME
    J Nucl Med; 2002 Nov; 43(11):1507-29. PubMed ID: 12411555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
    Macklis RM; Pohlman B
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphoma.
    Riley MB; Byar K
    Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):1-7. PubMed ID: 15160855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy for Non-Hodgkin's Lymphoma.
    Rao AV; Akabani G; Rizzieri DA
    Clin Med Res; 2005 Aug; 3(3):157-65. PubMed ID: 16160070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Fink-Bennett DM; Thomas K
    J Nucl Med Technol; 2003 Jun; 31(2):61-8; quiz 69-70. PubMed ID: 12777454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
    O'Donnell RT; Leigh BR; Christensen SD; Goldstein DS; Kukis DL; Shen S; Yuan A; DeNardo DA; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1999 Jun; 14(3):167-76. PubMed ID: 10850301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up.
    Martínez A; Martínez-Ramirez M; Martínez-Caballero D; Beneit P; Clavel J; Figueroa G; Verdú J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(1):13-19. PubMed ID: 27422155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm.
    DeNardo G; DeNardo S
    Semin Nucl Med; 2010 Mar; 40(2):136-44. PubMed ID: 20113681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
    Sharkey RM; Goldenberg DM
    J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.